Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease

Ruben J. Colman; Ye Xiong; Tomoyuki Mizuno; Jeffrey S. Hyams; Joshua D. Noe; Brendan Boyle; Geert R. D’Haens; Johan van Limbergen; Kelly Chun; Jane Yang; Michael J. Rosen; Lee A. Denson; Alexander A Vinks; Phillip Minar

doi:10.1111/apt.16733

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease

Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, Jeffrey S. Hyams, Joshua D. Noe, Brendan Boyle, Geert R. D’Haens, Johan van Limbergen, Kelly Chun, Jane Yang, Michael J. Rosen, Lee A. Denson, Alexander A Vinks, Phillip Minar

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Original language	English
Pages (from-to)	593-603
Number of pages	11
Journal	Alimentary Pharmacology and Therapeutics
Volume	55
Issue number	5
DOIs	https://doi.org/10.1111/apt.16733
Publication status	Published - Mar 2022
Externally published	Yes

ASJC Scopus Subject Areas

Hepatology
Gastroenterology
Pharmacology (medical)

Access to Document

10.1111/apt.16733

Cite this

Colman, R. J., Xiong, Y., Mizuno, T., Hyams, J. S., Noe, J. D., Boyle, B., D’Haens, G. R., van Limbergen, J., Chun, K., Yang, J., Rosen, M. J., Denson, L. A., Vinks, AA., & Minar, P. (2022). Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease. Alimentary Pharmacology and Therapeutics, 55(5), 593-603. https://doi.org/10.1111/apt.16733

Colman, RJ, Xiong, Y, Mizuno, T, Hyams, JS, Noe, JD, Boyle, B, D’Haens, GR, van Limbergen, J, Chun, K, Yang, J, Rosen, MJ, Denson, LA, Vinks, AA & Minar, P 2022, 'Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease', Alimentary Pharmacology and Therapeutics, vol. 55, no. 5, pp. 593-603. https://doi.org/10.1111/apt.16733

@article{14c38d2429e543e98bcc1c7dbf489cd8,

title = "Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn{\textquoteright}s disease",

author = "Colman, {Ruben J.} and Ye Xiong and Tomoyuki Mizuno and Hyams, {Jeffrey S.} and Noe, {Joshua D.} and Brendan Boyle and D{\textquoteright}Haens, {Geert R.} and {van Limbergen}, Johan and Kelly Chun and Jane Yang and Rosen, {Michael J.} and Denson, {Lee A.} and Alexander A Vinks and Phillip Minar",

note = "Funding Information: : RJC, YX, TM, BB, JDN, PM and MJR have no disclosures. JSH has served as an advisory board member for Janssen, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim. JSH has served as a consultant for Takeda, Thetis Pharmaceuticals, Allergan. GRD has served as an consultant for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist. GRD has served as a speaker for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda. JvL has served as a speaker and a consultant for Nestle Health Sciences, and has received research funding from Nestle Health Sciences. KC and JY are employees of Labcorp. JY owns stocks and shares in Labcorp. LAD has served as a speaker, a consultant and an advisory board member for the Crohn{\textquoteright}s and Colitis Foundation, and has received research funding from the National Institutes of Health, the CureForIBD Foundation, the Crohn{\textquoteright}s and Colitis Foundation, and the Helmsley Foundation. LAD owns US patent number 10626460 for use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease, 9995752 for methods and compositions for determining and treating relapse in inflammatory bowel disease, and 9541560 for serological markers of inflammatory bowel disease phenotype and disease progression. These patents are not related to the contents of the current manuscript. AAV has received research funding from the Gerber foundation. MJR has served on the advisory board of Pfizer and Entasis Therapeutics. Declaration of personal interests Funding Information: We would like to thank Yi-Ting Tsai, MS and Kimberly Jackson, BA for patient recruitment and processing of the biospecimens. Declaration of personal interests: RJC, YX, TM, BB, JDN, PM and MJR have no disclosures. JSH has served as an advisory board member for Janssen, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim. JSH has served as a consultant for Takeda, Thetis Pharmaceuticals, Allergan. GRD has served as an consultant for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist. GRD has served as a speaker for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda. JvL has served as a speaker and a consultant for Nestle Health Sciences, and has received research funding from Nestle Health Sciences. KC and JY are employees of Labcorp. JY owns stocks and shares in Labcorp. LAD has served as a speaker, a consultant and an advisory board member for the Crohn{\textquoteright}s and Colitis Foundation, and has received research funding from the National Institutes of Health, the CureForIBD Foundation, the Crohn{\textquoteright}s and Colitis Foundation, and the Helmsley Foundation. LAD owns US patent number 10626460 for use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease, 9995752 for methods and compositions for determining and treating relapse in inflammatory bowel disease, and 9541560 for serological markers of inflammatory bowel disease phenotype and disease progression. These patents are not related to the contents of the current manuscript. AAV has received research funding from the Gerber foundation. MJR has served on the advisory board of Pfizer and Entasis Therapeutics. Declaration of funding interests: This work was funded in part by the National Institutes of Health (T32 DK 007727 to R.J.C., K23 DK 105229 and R03 DK 118314 to P.M. and 5T32 HD 69054 to Y.X.), the Crohn{\textquoteright}s and Colitis Foundation to P.M. and the Academic Research Committee at Cincinnati Children{\textquoteright}s Research Foundation to P.M. Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Cincinnati Children{\textquoteright}s Hospital Medical Center were supported in part by the NIH (NIH/NCATS UL1 TR000445). This project was funded in part by the National Institutes of Health grant number P30 DK078392 (a clinical component of the Digestive Diseases Research Core Center in Cincinnati). Funding Information: : This work was funded in part by the National Institutes of Health (T32 DK 007727 to R.J.C., K23 DK 105229 and R03 DK 118314 to P.M. and 5T32 HD 69054 to Y.X.), the Crohn{\textquoteright}s and Colitis Foundation to P.M. and the Academic Research Committee at Cincinnati Children{\textquoteright}s Research Foundation to P.M. Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Cincinnati Children{\textquoteright}s Hospital Medical Center were supported in part by the NIH (NIH/NCATS UL1 TR000445). This project was funded in part by the National Institutes of Health grant number P30 DK078392 (a clinical component of the Digestive Diseases Research Core Center in Cincinnati). Declaration of funding interests Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons Ltd.",

year = "2022",

month = mar,

doi = "10.1111/apt.16733",

language = "English",

volume = "55",

pages = "593--603",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease

AU - Colman, Ruben J.

AU - Xiong, Ye

AU - Mizuno, Tomoyuki

AU - Hyams, Jeffrey S.

AU - Noe, Joshua D.

AU - Boyle, Brendan

AU - D’Haens, Geert R.

AU - van Limbergen, Johan

AU - Chun, Kelly

AU - Yang, Jane

AU - Rosen, Michael J.

AU - Denson, Lee A.

AU - Vinks, Alexander A

AU - Minar, Phillip

N1 - Funding Information: : RJC, YX, TM, BB, JDN, PM and MJR have no disclosures. JSH has served as an advisory board member for Janssen, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim. JSH has served as a consultant for Takeda, Thetis Pharmaceuticals, Allergan. GRD has served as an consultant for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist. GRD has served as a speaker for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda. JvL has served as a speaker and a consultant for Nestle Health Sciences, and has received research funding from Nestle Health Sciences. KC and JY are employees of Labcorp. JY owns stocks and shares in Labcorp. LAD has served as a speaker, a consultant and an advisory board member for the Crohn’s and Colitis Foundation, and has received research funding from the National Institutes of Health, the CureForIBD Foundation, the Crohn’s and Colitis Foundation, and the Helmsley Foundation. LAD owns US patent number 10626460 for use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease, 9995752 for methods and compositions for determining and treating relapse in inflammatory bowel disease, and 9541560 for serological markers of inflammatory bowel disease phenotype and disease progression. These patents are not related to the contents of the current manuscript. AAV has received research funding from the Gerber foundation. MJR has served on the advisory board of Pfizer and Entasis Therapeutics. Declaration of personal interests Funding Information: We would like to thank Yi-Ting Tsai, MS and Kimberly Jackson, BA for patient recruitment and processing of the biospecimens. Declaration of personal interests: RJC, YX, TM, BB, JDN, PM and MJR have no disclosures. JSH has served as an advisory board member for Janssen, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim. JSH has served as a consultant for Takeda, Thetis Pharmaceuticals, Allergan. GRD has served as an consultant for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist. GRD has served as a speaker for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda. JvL has served as a speaker and a consultant for Nestle Health Sciences, and has received research funding from Nestle Health Sciences. KC and JY are employees of Labcorp. JY owns stocks and shares in Labcorp. LAD has served as a speaker, a consultant and an advisory board member for the Crohn’s and Colitis Foundation, and has received research funding from the National Institutes of Health, the CureForIBD Foundation, the Crohn’s and Colitis Foundation, and the Helmsley Foundation. LAD owns US patent number 10626460 for use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease, 9995752 for methods and compositions for determining and treating relapse in inflammatory bowel disease, and 9541560 for serological markers of inflammatory bowel disease phenotype and disease progression. These patents are not related to the contents of the current manuscript. AAV has received research funding from the Gerber foundation. MJR has served on the advisory board of Pfizer and Entasis Therapeutics. Declaration of funding interests: This work was funded in part by the National Institutes of Health (T32 DK 007727 to R.J.C., K23 DK 105229 and R03 DK 118314 to P.M. and 5T32 HD 69054 to Y.X.), the Crohn’s and Colitis Foundation to P.M. and the Academic Research Committee at Cincinnati Children’s Research Foundation to P.M. Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Cincinnati Children’s Hospital Medical Center were supported in part by the NIH (NIH/NCATS UL1 TR000445). This project was funded in part by the National Institutes of Health grant number P30 DK078392 (a clinical component of the Digestive Diseases Research Core Center in Cincinnati). Funding Information: : This work was funded in part by the National Institutes of Health (T32 DK 007727 to R.J.C., K23 DK 105229 and R03 DK 118314 to P.M. and 5T32 HD 69054 to Y.X.), the Crohn’s and Colitis Foundation to P.M. and the Academic Research Committee at Cincinnati Children’s Research Foundation to P.M. Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Cincinnati Children’s Hospital Medical Center were supported in part by the NIH (NIH/NCATS UL1 TR000445). This project was funded in part by the National Institutes of Health grant number P30 DK078392 (a clinical component of the Digestive Diseases Research Core Center in Cincinnati). Declaration of funding interests Publisher Copyright: © 2021 John Wiley & Sons Ltd.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85121547521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121547521&partnerID=8YFLogxK

U2 - 10.1111/apt.16733

DO - 10.1111/apt.16733

M3 - Article

C2 - 34935161

AN - SCOPUS:85121547521

SN - 0269-2813

VL - 55

SP - 593

EP - 603

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 5

ER -

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this